Elanco Animal Health (ELAN) Competitors

$21.67 -1.98 (-8.37%)

Closing price 03:59 PM Eastern

Extended Trading

$22.03 +0.36 (+1.66%)

As of 05:31 PM Eastern

ELAN vs. TEVA, ONC, RVMD, INSM, and BNTX

Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Revolution Medicines (RVMD), Insmed (INSM), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does Elanco Animal Health compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Elanco Animal Health's net margin of -4.95%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Elanco Animal Health	-4.95%	7.42%	3.66%

Teva Pharmaceutical Industries has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.35B	2.38	$1.41B	$1.33	27.00
Elanco Animal Health	$4.89B	2.21	-$232M	-$0.50	N/A

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Elanco Animal Health had 6 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 26 mentions for Elanco Animal Health and 20 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.73 beat Elanco Animal Health's score of 0.50 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	5 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 16.34%. Elanco Animal Health has a consensus price target of $28.20, indicating a potential upside of 30.13%. Given Elanco Animal Health's higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Teva Pharmaceutical Industries beats Elanco Animal Health on 10 of the 16 factors compared between the two stocks.

How does Elanco Animal Health compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

BeOne Medicines has a net margin of 8.94% compared to Elanco Animal Health's net margin of -4.95%. BeOne Medicines' return on equity of 12.06% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Elanco Animal Health	-4.95%	7.42%	3.66%

BeOne Medicines has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.38	$286.93M	$4.47	69.52
Elanco Animal Health	$4.89B	2.21	-$232M	-$0.50	N/A

BeOne Medicines has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Elanco Animal Health had 5 more articles in the media than BeOne Medicines. MarketBeat recorded 26 mentions for Elanco Animal Health and 21 mentions for BeOne Medicines. Elanco Animal Health's average media sentiment score of 0.50 beat BeOne Medicines' score of 0.36 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	5 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines presently has a consensus target price of $391.00, indicating a potential upside of 25.82%. Elanco Animal Health has a consensus target price of $28.20, indicating a potential upside of 30.13%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

BeOne Medicines beats Elanco Animal Health on 11 of the 16 factors compared between the two stocks.

How does Elanco Animal Health compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Elanco Animal Health has higher revenue and earnings than Revolution Medicines. Elanco Animal Health is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Elanco Animal Health	$4.89B	2.21	-$232M	-$0.50	N/A

Revolution Medicines currently has a consensus target price of $103.88, suggesting a potential downside of 27.94%. Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 30.13%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	3.10
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Revolution Medicines has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Elanco Animal Health	-4.95%	7.42%	3.66%

Revolution Medicines has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Revolution Medicines had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 27 mentions for Revolution Medicines and 26 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.50 beat Revolution Medicines' score of 0.18 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Elanco Animal Health	5 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Elanco Animal Health beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

How does Elanco Animal Health compare to Insmed?

Insmed (NASDAQ:INSM) and Elanco Animal Health (NYSE:ELAN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 103.93%. Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 30.13%. Given Insmed's stronger consensus rating and higher probable upside, research analysts plainly believe Insmed is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has a net margin of -4.95% compared to Insmed's net margin of -144.44%. Elanco Animal Health's return on equity of 7.42% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Elanco Animal Health	-4.95%	7.42%	3.66%

In the previous week, Insmed had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 32 mentions for Insmed and 26 mentions for Elanco Animal Health. Insmed's average media sentiment score of 0.58 beat Elanco Animal Health's score of 0.50 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	14 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Elanco Animal Health	5 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elanco Animal Health has higher revenue and earnings than Insmed. Elanco Animal Health is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	37.13	-$1.28B	-$5.75	N/A
Elanco Animal Health	$4.89B	2.21	-$232M	-$0.50	N/A

Insmed has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

97.5% of Elanco Animal Health shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Insmed beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Elanco Animal Health compare to BioNTech?

Elanco Animal Health (NYSE:ELAN) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Elanco Animal Health has a net margin of -4.95% compared to BioNTech's net margin of -44.39%. Elanco Animal Health's return on equity of 7.42% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
BioNTech	-44.39%	-5.30%	-4.62%

Elanco Animal Health currently has a consensus target price of $28.20, suggesting a potential upside of 30.13%. BioNTech has a consensus target price of $131.60, suggesting a potential upside of 40.99%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

In the previous week, Elanco Animal Health and Elanco Animal Health both had 26 articles in the media. Elanco Animal Health's average media sentiment score of 0.50 beat BioNTech's score of 0.29 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	5 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	5 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Elanco Animal Health has higher revenue and earnings than BioNTech. Elanco Animal Health is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.89B	2.21	-$232M	-$0.50	N/A
BioNTech	$2.81B	8.41	-$1.29B	-$5.88	N/A

Summary

Elanco Animal Health beats BioNTech on 10 of the 15 factors compared between the two stocks.

Get Elanco Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELAN vs. The Competition

Export

Metric	Elanco Animal Health	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$10.82B	$5.62B	$6.18B	$22.92B
Dividend Yield	N/A	1.55%	2.78%	4.02%
P/E Ratio	-43.34	33.35	20.66	28.93
Price / Sales	2.21	22.67	527.64	24.53
Price / Cash	10.19	16.51	27.81	19.21
Price / Book	1.64	3.06	9.77	4.65
Net Income	-$232M	$218.81M	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-6.23%	3.40%	6.28%	3.95%
1 Year Performance	80.29%	18.79%	41.81%	28.96%

Elanco Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELAN Elanco Animal Health	3.7201 of 5 stars	$21.67 -8.4%	$28.20 +30.1%	+95.8%	$10.82B	$4.89B	N/A	9,400	Earnings Report
TEVA Teva Pharmaceutical Industries	4.1188 of 5 stars	$35.36 +1.2%	$41.56 +17.5%	+110.8%	$40.19B	$17.35B	26.58	33,950
ONC BeOne Medicines	4.2959 of 5 stars	$297.14 +1.1%	$390.58 +31.4%	+34.5%	$32.24B	$5.34B	117.91	12,000	Positive News Analyst Upgrade
RVMD Revolution Medicines	2.1749 of 5 stars	$147.90 +6.0%	$78.94 -46.6%	+249.5%	$29.65B	$11.58M	N/A	250	Earnings Report Analyst Revision
INSM Insmed	3.2917 of 5 stars	$140.01 +5.1%	$213.23 +52.3%	+55.5%	$28.76B	$606.42M	N/A	1,664	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELAN) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elanco Animal Health (ELAN) Competitors

ELAN vs. TEVA, ONC, RVMD, INSM, and BNTX

How does Elanco Animal Health compare to Teva Pharmaceutical Industries?

Summary

How does Elanco Animal Health compare to BeOne Medicines?

Summary

How does Elanco Animal Health compare to Revolution Medicines?

Summary

How does Elanco Animal Health compare to Insmed?

Summary

How does Elanco Animal Health compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAN vs. The Competition

Elanco Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elanco Animal Health (ELAN) Competitors

ELAN vs. TEVA, ONC, RVMD, INSM, and BNTX

How does Elanco Animal Health compare to Teva Pharmaceutical Industries?

Is TEVA or ELAN more profitable?

Which has preferable earnings & valuation, TEVA or ELAN?

Which has more volatility and risk, TEVA or ELAN?

Do insiders & institutionals have more ownership in TEVA or ELAN?

Does the media refer more to TEVA or ELAN?

Do analysts rate TEVA or ELAN?

Summary

How does Elanco Animal Health compare to BeOne Medicines?

Is ONC or ELAN more profitable?

Which has better valuation & earnings, ONC or ELAN?

Which has more risk & volatility, ONC or ELAN?

Do institutionals and insiders have more ownership in ONC or ELAN?

Does the media refer more to ONC or ELAN?

Do analysts rate ONC or ELAN?

Summary

How does Elanco Animal Health compare to Revolution Medicines?

Which has higher earnings & valuation, RVMD or ELAN?

Do analysts prefer RVMD or ELAN?

Is RVMD or ELAN more profitable?

Which has more volatility and risk, RVMD or ELAN?

Do institutionals & insiders hold more shares of RVMD or ELAN?

Does the media favor RVMD or ELAN?

Summary

How does Elanco Animal Health compare to Insmed?

Do analysts prefer INSM or ELAN?

Is INSM or ELAN more profitable?

Does the media favor INSM or ELAN?

Which has stronger earnings and valuation, INSM or ELAN?

Which has more risk and volatility, INSM or ELAN?

Do insiders and institutionals hold more shares of INSM or ELAN?

Summary

How does Elanco Animal Health compare to BioNTech?

Do insiders & institutionals hold more shares of ELAN or BNTX?

Is ELAN or BNTX more profitable?

Do analysts recommend ELAN or BNTX?

Does the media prefer ELAN or BNTX?

Which has more volatility & risk, ELAN or BNTX?

Which has better valuation & earnings, ELAN or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAN vs. The Competition

Elanco Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools